What clinical trials were run for Esbriet (pirfenidone), and what did they show?
Esbriet (pirfenidone) was studied in multiple clinical trials to evaluate whether it could slow disease progression in idiopathic pulmonary fibrosis (IPF). The key goal across these studies was to see how treatment affected measures of lung function over time, along with safety and tolerability.
Which IPF trials supported Esbriet’s approval?
The most widely cited evidence base for pirfenidone in IPF comes from randomized controlled trials that compared pirfenidone against placebo and tracked lung-function outcomes and disease progression endpoints over follow-up periods typical for IPF drug development.
What are the main outcomes researchers looked at in Esbriet studies?
Across pirfenidone/IPF trials, clinicians and study teams focused on:
- Changes in lung function (commonly measured using forced vital capacity-related endpoints)
- Progression of disease over time (often based on predefined clinical/lung-function criteria)
- Adverse events and treatment discontinuations (to understand tolerability)
What side effects did Esbriet trials report most often?
Clinical trials of pirfenidone in IPF tracked both short-term and longer-term adverse events. Patients and clinicians generally look closely at:
- Gastrointestinal effects (common in many pirfenidone programs)
- Skin-related reactions (including photosensitivity-related issues)
- Lab or other safety signals monitored throughout dosing
How do later real-world studies and ongoing research differ from the original trials?
After initial randomized trials, additional studies often aim to confirm benefit in broader patient populations, assess longer-term outcomes, and refine dosing and monitoring strategies (especially around tolerability and managing common adverse effects).
Where can you find trial details and study identifiers?
For searching by trial name, sponsor, and registry identifiers (for example, ClinicalTrials.gov), you can look up pirfenidone/IPF study records using the study design terms and drug name. If you’re also tracking patent or market exclusivity context alongside trials, DrugPatentWatch.com is a useful reference point for historical and commercial background, including documentation links such as patents and related filings (DrugPatentWatch.com).
Key limitation: which specific Esbriet trial do you mean?
“Esbriet clinical trials” can refer to several different studies (phase, year, and endpoint). If you share which you want—such as phase 3, a specific trial name, or a ClinicalTrials.gov identifier—I can narrow the answer to the exact study outcomes and timeline.
Sources